HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Marie Stiborová Selected Research

aristolochic acid I (aristolochic acid)

9/2021Co-Exposure to Aristolochic Acids I and II Increases DNA Adduct Formation Responsible for Aristolochic Acid I-Mediated Carcinogenicity in Rats.
11/2020In Vivo Metabolism of Aristolochic Acid I and II in Rats Is Influenced by Their Coexposure.
11/2019The impact of p53 on aristolochic acid I-induced nephrotoxicity and DNA damage in vivo and in vitro.
10/2017DNA Adducts Formed by Aristolochic Acid Are Unique Biomarkers of Exposure and Explain the Initiation Phase of Upper Urothelial Cancer.
1/2017Comparison of the oxidation of carcinogenic aristolochic acid I and II by microsomal cytochromes P450 in vitro: experimental and theoretical approaches.
2/2016Induction of cytochromes P450 1A1 and 1A2 suppresses formation of DNA adducts by carcinogenic aristolochic acid I in rats in vivo.
2/2016Active Site Mutations as a Suitable Tool Contributing to Explain a Mechanism of Aristolochic Acid I Nitroreduction by Cytochromes P450 1A1, 1A2 and 1B1.
11/2015A Mechanism of O-Demethylation of Aristolochic Acid I by Cytochromes P450 and Their Contributions to This Reaction in Human and Rat Livers: Experimental and Theoretical Approaches.
11/2015The influence of ochratoxin A on DNA adduct formation by the carcinogen aristolochic acid in rats.
7/2014The effect of aristolochic acid I on expression of NAD(P)H:quinone oxidoreductase in mice and rats--a comparative study.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Marie Stiborová Research Topics

Disease

40Neoplasms (Cancer)
09/2021 - 01/2002
16Balkan Nephropathy (Balkan Endemic Nephropathy)
09/2021 - 11/2007
9Neuroblastoma
01/2019 - 09/2008
5Body Weight (Weight, Body)
02/2011 - 01/2004
4Carcinogenesis
01/2018 - 11/2007
2Thyroid Neoplasms (Thyroid Cancer)
02/2020 - 07/2019
2Leukemia
06/2011 - 07/2007
1Glycosuria
11/2019
1medullary Thyroid cancer
07/2019
1Urinary Bladder Neoplasms (Bladder Cancer)
01/2018
1Carcinoma (Carcinomatosis)
11/2015
1Cystic Fibrosis (Mucoviscidosis)
01/2015
1Hypoxia (Hypoxemia)
04/2014
1Renal Insufficiency (Renal Failure)
03/2013
1Colonic Neoplasms (Colon Cancer)
12/2011
1Adenocarcinoma
06/2011
1Glioblastoma (Glioblastoma Multiforme)
06/2011
1Chronic Kidney Failure (Chronic Renal Failure)
06/2008
1Fibrosis (Cirrhosis)
06/2008
1Colorectal Neoplasms (Colorectal Cancer)
12/2006
1Edema (Dropsy)
01/2004
1Endometrial Neoplasms (Endometrial Cancer)
07/2002
1Prostatic Neoplasms (Prostate Cancer)
01/2002

Drug/Important Bio-Agent (IBA)

25aristolochic acid I (aristolochic acid)IBA
09/2021 - 04/2002
14DNA AdductsIBA
01/2019 - 07/2002
14ellipticineIBA
01/2019 - 12/2005
12EnzymesIBA
02/2020 - 01/2008
11CarcinogensIBA
01/2018 - 04/2002
9Pharmaceutical PreparationsIBA
02/2020 - 07/2002
5Cytochrome P-450 Enzyme System (Cytochrome P450)IBA
02/2020 - 09/2009
5DNA (Deoxyribonucleic Acid)IBA
01/2018 - 05/2009
4Plant ExtractsIBA
09/2021 - 01/2014
4AlkaloidsIBA
10/2017 - 01/2004
3CytochromesIBA
07/2019 - 01/2005
3Histone Deacetylase InhibitorsIBA
01/2018 - 09/2009
2vandetanib (ZD6474)IBA
02/2020 - 07/2019
2Cytochrome P-450 CYP3AIBA
07/2019 - 09/2009
2Valproic Acid (Depakote)FDA LinkGeneric
01/2018 - 09/2009
2Histone Deacetylases (Histone Deacetylase)IBA
01/2018 - 06/2010
2XenobioticsIBA
01/2018 - 09/2009
2Peroxidase (Myeloperoxidase)IBA
01/2014 - 06/2011
2Antineoplastic Agents (Antineoplastics)IBA
01/2014 - 06/2010
21-phenylazo-2-naphthol (Sudan I)IBA
02/2013 - 09/2009
2Environmental Pollutants (Pollutants, Environmental)IBA
06/2012 - 03/2009
22-anisidine (o-anisidine)IBA
06/2012 - 03/2009
212-hydroxyellipticineIBA
06/2011 - 07/2007
2Doxorubicin (Adriamycin)FDA LinkGeneric
06/2010 - 09/2008
2Cytochrome P-450 CYP1A1 (CYP1A1)IBA
09/2009 - 12/2006
1Aristolochic AcidsIBA
09/2021
1NAD (NADH)IBA
02/2020
1dimethylaniline monooxygenase (N-oxide forming) (flavin-containing monooxygenase)IBA
02/2020
1NADP (NADPH)IBA
02/2020
1OxidesIBA
02/2020
1Lactic Acid (Lactate)FDA LinkGeneric
11/2019
1Tyrosine Kinase InhibitorsIBA
07/2019
1Mixed Function Oxygenases (Monooxygenases)IBA
07/2019
14,6-dinitro-o-cresol (DNOC)IBA
07/2019
1ApoferritinsIBA
01/2019
1Phenobarbital (Luminal)FDA Link
01/2018
1Keratin-5 (Keratin 5)IBA
01/2018
1Oxidoreductases (Dehydrogenase)IBA
01/2018
1ProdrugsIBA
01/2018
1Biomarkers (Surrogate Marker)IBA
10/2017
1AntibodiesIBA
01/2015
1Cytochromes b5 (Cytochrome b5)IBA
12/2014
1Oxygen (Dioxygen)IBA
04/2014
1Histones (Histone)IBA
04/2014
1Transcription Factors (Transcription Factor)IBA
04/2014
1EllipticinesIBA
01/2014
1Type II DNA Topoisomerases (Topoisomerase II)IBA
01/2014
1Environmental CarcinogensIBA
02/2013
1Azo CompoundsIBA
02/2013
1Cytostatic AgentsIBA
02/2012
1benzocycloheptapyridineIBA
12/2011
12- amino- 1- methyl- 6- phenylimidazo(4,5- b)pyridineIBA
12/2011
1Cyclophosphamide (Cytoxan)FDA LinkGeneric
06/2010
1Etoposide (VP 16)FDA LinkGeneric
06/2010
1MutagensIBA
09/2009
1trichostatin A (A 300)IBA
09/2009
1theasinensin AIBA
09/2009
1PhytochemicalsIBA
09/2009
1Proteins (Proteins, Gene)FDA Link
05/2009
1Coenzymes (Enzyme Cofactors)IBA
05/2009
1Messenger RNA (mRNA)IBA
05/2009
1AminesIBA
03/2009
12-nitroanisoleIBA
03/2009
1DeoxyguanosineIBA
07/2007
113-hydroxyellipticineIBA
07/2007
1PeroxidasesIBA
12/2005
1NADPH-Ferrihemoprotein Reductase (Cytochrome P450 Reductase)IBA
01/2005
1Prostaglandin-Endoperoxide Synthases (Cyclooxygenase)IBA
01/2005
1sanguinarineIBA
01/2004
13-isopropenyl-3-methyldiamantaneIBA
07/2002
1TamoxifenFDA LinkGeneric
07/2002
12-isopropenyl-2-methyladamantaneIBA
07/2002
1Hormones (Hormone)IBA
01/2002
1FlavonoidsIBA
01/2002

Therapy/Procedure

2Therapeutics
01/2018 - 06/2010